Tab 2.
Exploration, replication, and combined sample: associations of leptin SNPs with treatment response (all patients, monotherapy groups) and cognitive performance. Means, SD- (every second column when available), and nominal p-values are depicted.
| Exploration sample | |||||||||
| All patients (n=251) | |||||||||
| rs10487506 genotype | AA (n=55) | AG (n=113) | GG (n=83) | F3,248 | p-Value | ||||
| Time until partial response | Weeks | 3.90 | 2.65 | 2.56 | 1.83 | 2.59 | 2.11 | 17.12 | 0.000039 |
| Time until response | Weeks | 6.09 | 3.96 | 4.72 | 2.64 | 4.47 | 3.14 | 7.20 | 0.0065 |
| Remission | % | 23.4 | 50.4 | 50.6 | 0.00040 | ||||
| Treatment attempts | n | 3.00 | 2.74 | 2.73 | 2.31 | 2.00 | 1.36 | 3.93 | 0.049 |
| SSRI (n=72) | |||||||||
| rs10487506 genotype | AA (n=13) | AG (n=32) | GG (n=27) | F3,69 | p-Value | ||||
| Time until partial response | Weeks | 3.98 | 3.02 | 2.15 | 0.98 | 2.84 | 2.53 | 4.15 | 0.067 |
| Time until response | Weeks | 5.00 | 3.84 | 4.64 | 2.87 | 4.23 | 2.69 | 0.18 | 0.84 |
| Remission | % | 30.8 | 53.1 | 55.6 | 0.13 | ||||
| Treatment attempts | n | 2.20 | 1.64 | 2.74 | 3.09 | 1.85 | 0.90 | 0.06 | 0.69 |
| Tricyclic antidepressants (n=31) | |||||||||
| rs10487506 genotype | AA (n=6) | AG (n=15) | GG (n=10) | F3,28 | p-Value | ||||
| Time until partial response | Weeks | 4.53 | 2.36 | 2.94 | 1.85 | 3.08 | 2.47 | 3.66 | 0.081 |
| Time until response | Weeks | NAn | NAn | 4.17 | 3.01 | 5.60 | 4.51 | NAn | NAn |
| Remission | % | 0.0 | 46.7 | 50.0 | 0.030 | ||||
| Treatment attempts | n | 5.33 | 5.13 | 3.70 | 2.83 | 2.13 | 1.81 | 0.41 | 0.88 |
| Mirtazapine (n=64) | |||||||||
| rs10487506 genotype | AA (n=11) | AG (n=30) | GG (n=23) | F3,61 | p-Value | ||||
| Time until partial response | Weeks | 4.54 | 3.19 | 3.17 | 2.42 | 2.13 | 1.68 | 4.65 | 0.025 |
| Time until response | Weeks | 8.16 | 3.38 | 4.53 | 2.38 | 3.65 | 2.30 | 19.69 | 0.000014 |
| Remission | % | 9.1 | 56.7 | 56.5 | 0.0041 | ||||
| Treatment attempts | n | 2.42 | 1.31 | 2.57 | 1.95 | 2.06 | 1.26 | 0.01 | 0.98 |
| Cognitive performance | |||||||||
| rs4731423 genotype | AA (n=53) | AG (n=73) | GG (n=37) | F4,159 | p-Value | ||||
| Memory test (score) | 6.48 | 0.27 | 7.53 | 0.23 | 7.64 | 0.35 | 12.58 | 0.0040 | |
| rs3828942 genotype | AA (n=43) | AG (n=52) | GG (n=23) | F4,114 | p-Value | ||||
| STROOP test (interference score) | 101.52 | 5.21 | 85.27 | 4.13 | 86.55 | 4.58 | 6.99 | 0.0045 | |
| Replication sample | |||||||||
| All patients (n=358) | |||||||||
| rs10487506 genotype | AA (n=79) | AG (n=171) | GG (n=108) | p-Value | |||||
| Remission | % | 50.6 | 55.6 | 58.3 | 0.34 | ||||
| SSRI (n=54) | |||||||||
| rs10487506 genotype | AA (n=16) | AG (n=26) | GG (n=12) | p-Value | |||||
| Remission | % | 56.3 | 61.5 | 66.7 | 0.63 | ||||
| Tricyclic antidepressants (n=65) | |||||||||
| rs10487506 genotype | AA (n=21) | AG (n=26) | GG (n=18) | p-Value | |||||
| Remission | % | 38.1 | 61.5 | 77.8 | 0.021 | ||||
| Mirtazapine (n=74) | |||||||||
| rs10487506 genotype | AA (n=18) | AG (n=37) | GG (n=19) | p-Value | |||||
| Remission | % | 55.6 | 45.9 | 52.6 | 0.59 | ||||
| Combined sample | |||||||||
| All patients (n=609) | |||||||||
| rs10487506 genotype | AA (n=134) | AG (n=283) | GG (n=192) | p-Value | |||||
| Remission | % | 39.6 | 53.5 | 55.0 | 0.0029 | ||||
| SSRI (n=126) | |||||||||
| rs10487506 genotype | AA (n=29) | AG (n=58) | GG (n=39) | p-Value | |||||
| Remission | % | 44.8 | 56.9 | 59.0 | 0.22 | ||||
| Tricyclic antidepressants (n=96) | |||||||||
| rs10487506 genotype | AA (n=27) | AG (n=41) | GG (n=28) | p-Value | |||||
| Remission | % | 29.6 | 56.1 | 67.9 | 0.0059 | ||||
| Mirtazapine (n=138) | |||||||||
| rs10487506 genotype | AA (n=29) | AG (n=67) | GG (n=42) | p-Value | |||||
| Remission | % | 37.9 | 50.7 | 54.8 | 0.17 | ||||
*
There were no patients in this genotype-subgroup, who achieved the response criterion.